

57
RECEIVED

OCT 15 2002

ATTORNEY'S DOCKET NUMBER: 2002941-0051

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Bachovchin <i>et al.</i>	Examiner:	Lukton, D.
Serial No.:	08/950,542	Art Unit:	1653
Filed:	October 15, 1997		
For:	INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV		

DECLARATION UNDER 37 C.F.R. 1.132

I, Robert R. Rando, declare as follows:

1. I am a scientific consultant to Point Therapeutics, Inc., a licensee of the above-identified patent application, in the field of boroprolin-containing peptides. I make this Declaration in support of an Amendment that has been filed in connection with the above-identified patent application.
2. I am a Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, Boston, MA. I have published extensively in the area of chemistry and biology of vision and signal transduction. Throughout my career, I have authored numerous peer reviewed articles and have made technical presentations at professional meetings in this field. I have extensive experience in enzyme characterization and am familiar with methods such as high performance liquid chromatograph (HPLC), enzyme activity assays, and chemical synthesis. A copy of my curriculum vitae, including a list of my publications, is attached hereto as EXHIBIT A.
3. Prior to making this declaration, I studied the following documents:
 - U.S. Patent Application Serial No. 08/950,542, entitled, "Inhibitors of Dipeptidyl-Aminopeptidase Type IV", including a list of the claims pending as of May 14, 2002;
 - W. Bachovchin, *et al.*, J. Biol. Chem. 265:3738 (1990) ("Bachovchin JBC"); and
 - W. Bachovchin Declaration (dated April 1, 1999).

4. I understand that the invention claimed in the above identified patent application is directed to compositions containing a mixture of boroproline-containing peptides, in which at least 96% of the carbon atoms bearing the boron are of the L-configuration.

5. I have made certain observations and conclusions, which are stated below, based upon my study of the above-identified documents, my general academic training and my technical expertise.

6. I have reviewed the Bachovchin JBC reference and the Bachovchin Declaration and have concluded that the Bachovchin JBC does not disclose the purification of a boroproline-containing L-isomer. The Bachovchin Declaration includes an explanation as to why Dr. Bachovchin's original presumption that he had purified the L-isomer was incorrect and provides experimental evidence to support this explanation. (See Bachovchin Declaration, paragraphs 5-18). Accordingly, I have concluded that the Bachovchin JBC reference does not disclose the purification of an L-isomer of a boroproline-containing peptide using silica gel chromatography or any other method.

7. I have reviewed the above-identified patent application and, in particular, I have reviewed the descriptions of the purification methods appearing on pages 15 and 21 of the application. I have concluded that the description of the invention in the application is sufficient to allow a chemist of ordinary skill to make and use the claimed boroproline-containing L isomers for the following reasons.

8. The descriptions on pages 15 and 21 of the application disclose methods for purifying a boroproline-containing L isomer; however, the description on page 21 is unambiguous in its teachings that the HPLC C18 method can be used for this purpose, whereas the description on page 15 is equivocal. In particular, the page 15 description states (emphasis added):

"The two diastereomers of Ala-boroPro-pinacol, L-Ala-D-boroPro-pinacol and L-Ala-L-boroPro-pinacol, can be partially separated by silica gel chromatography with 20% methanol in ethyl acetate as eluant. The early fraction *appears* by NMR analysis to be 95% enriched in one isomer. Because this fraction has more [sic] inhibits DP-IV to a greater extent than later fractions (at equal concentrations) it is *probably* enriched in the L-boroPro (L-Ala-L-boroPro-pinacol) isomer."

The use of equivocal language such as "appears" and "probably" suggests to me that the page 15 procedure is not the definitive procedure for purifying the L isomer of a boroproline-containing peptide. In contrast, the description on page 21 of the application unambiguously states that HPLC C18 chromatograph can be used to separate the L from D isomers:

"High pressure liquid chromatography (HPLC) can be used to separate L-Pro-D-boroPro from L-Pro-L-boroPro. ... NMR and mass spectra analysis were consistent with both compounds being Pro-boroPro. Rechromatography of the purified isomers indicated that the first pass on the HPLC column achieved an isomeric purity of about 99-6% for each isomer. High pressure liquid chromatography (HPLC) can similarly be used ... to separate [sic] the L-Ala-D-boroPro from L-Ala-L-boroPro or to separate [sic] the D-boroPro from of other inhibitors from the L-boroPro form."

In view of these descriptions, I have concluded that there remained uncertainties regarding the utility of conventional silica gel chromatography described on page 15 for separating the L and D isomers but that the HPLC method described on page 21 of the application would be useful for this purpose.

9. As noted in the previous paragraph, page 21 of the application states, "the HPLC column achieved an isomeric purity of about 99-6% for each isomer". Although it is conventional to place the lower value number first in giving a range, the expression "99-6%" is consistent with an interpretation that the phrase "99-6%" refers to a range of about 96% to 99%. This interpretation also is consistent with a later publication by W. Gutheil and W. Bachovchin, "Separation of L-Pro-DL-boroPro into Its Component Diastereomers and Kinetic Analysis of Their Inhibition of Dipeptidyl Peptidase IV: A New Method for the Analysis of Slow, Tight-binding Inhibitors." *Biochemistry* 32:8723 (1993). This paper describes the separation of the L and D diastereomers by C18 HPLC and reports that a "purity of >98% for the purified products was indicated by analytical HPLC" (page 8727, right column, paragraph following Figure 3 legend). An interpretation that the phrase, "99-6%" refers to a range is consistent with the report of a purity >98% in Dr. Bachovchin's later publication of the separation process. The above-identified patent application contains various typographical errors; however even with these errors, the description of the invention would be understood by a practicing scientist.

10. It is my understanding that the U.S. Patent and Trademark Office has taken the position that one skilled in the art would have been motivated to purify the boroproline-containing L

isomers with the HPLC method described in the application because the L isomer is the active

USPTO

greater potency. While it is true that the L-isomer might be expected to possess greater potency than the D-isomer, it must be remembered that the boroprolin-containing peptides are designed for therapeutic use. This intended use is described on page 22 of the application. One skilled in the art would expect the D-isomers to have a longer half-life in vivo. In view of the intended therapeutic use of these compounds, it is my opinion that one skilled in the art would be motivated to isolate the D-isomers because of their greater half-life in vivo even if the D-isomers had a reduced potency compared to the L-isomers.

11. It also is my understanding that the U.S. Patent and Trademark Office has taken the position that one skilled in the art would have been motivated to use HPLC C18 chromatography to purify the boroprolin-containing L isomers at the time the invention was made and also would have had a reasonable expectation that this method would be useful for achieving purification of the L isomer. I disagree with this conclusion for the following reasons. Although HPLC C18 columns were in general use at the time the priority application was filed (October 1991), a variety of purification techniques, such as HPLC using fine bore silica, chromatography using chiral matrix materials to separate stereoisomers, HPLC using other types of resins such as C8 columns, ion-exchange chromatography, and thin layer chromatography also were available. Even if one skilled in the art had been motivated to try one of these methods to separate the L and D isomers at the time the invention was made, it would not have been possible to know in advance which method would be useful for this purpose. Although one could have tried a variety of methods to separate the L and D isomers, the selection of a useful method would have required experimental testing.

12. I, the undersigned, declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this document and any patent which may issue from the above-identified patent application.

Dated: 5/21/02Robert R. Rando
Robert R. Rando



CURRICULUM VITAE

Robert Richard Rando

Date of Birth: March 4, 1941

Place of Birth: New York, New York

Residence: 60 Montvale Road, Newton Centre, MA 02159
(617) 965-5798

Office: Department of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School,
240 Longwood Avenue, Boston, MA 02115

Telephone: (617) 432-1794; Fax: (617) 432-0471

Email: rando@hms.harvard.edu

EDUCATION:

1962 B.S., Chemistry, Rutgers University, New Brunswick, NJ
1966 Ph.D., Physical-Organic Chemistry, Yale University, New Haven, CT
1981 A.M. (Hon.) Harvard University, Cambridge, MA

POSTDOCTORAL:

1966-68 Research Associate, Department of Chemistry, Harvard
University, Cambridge, MA

APPOINTMENTS:

1968-72 Assistant Professor of Chemistry, Washington Square
College of Arts and Sciences and the Graduate School of
Arts and Sciences of New York University, NY

1972-75 Assistant Professor of Pharmacology, Harvard Medical
School, Boston, MA

1974-90 Tutor in the Biochemical Sciences, Harvard University,
Cambridge, MA

1975-80 Associate Professor of Pharmacology, Harvard Medical
School, Boston, MA

1980-87 Professor of Pharmacology, Harvard Medical School,
Boston, MA

1983-87 Gustavus Adolphus Pfeiffer Professor of Pharmacology,
Harvard Medical School, Boston, MA

- 1987- Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA
- 1987- Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA

FELLOWSHIPS AND AWARDS:

- 1963 National Science Foundation Predoctoral Fellowship
- 1963-66 U.S. Public Health Service Predoctoral Fellowship
- 1966-68 U.S. Public Health Service Postdoctoral Fellowship
- 1975-80 U.S. Public Health Service Research Career Development Award
- 1990-99 U.S. Public Health Service MERIT Award
- 1991 Alcon Research Institute Award in Vision Research

MEMBERSHIPS:

- 1963- American Chemical Society
- 1972- American Association for the Advancement of Science
- 1973- American Society for Pharmacology and Experimental Therapeutics
- 1980- Association for Research in Vision and Ophthalmology
- 1996 American Academy of Arts and Sciences

CURRENT EDITORIAL, GRANT REVIEW, AND FOUNDATION BOARDS:

- 1989- RP Foundation Fighting Blindness (Member of Scientific Advisory Board)
- 1991- Alcon Research Institute (Member)
- 1994- Chemistry & Biology (Editorial Board)
- 1997- NIH Visual Sciences C Study Section (Member)
- 1999 Research to Prevent Blindness (Member of Scientific Advisory Board)

PUBLICATIONS

1. Rando, R.R. and Doering, W. von E.: β,γ -Unsaturated acids and esters by photochemical isomerization of α,β -conjugates. *J. Org. Chem.* 33:1671-1673, 1968.
2. Helmkamp, G.M., Rando, R.R., Brock, D.J.H. and Bloch, K.: β -Hydroxydecanoyl thioester dehydrase: Specificity of substrates and acetylenic inhibitors. *J. Biol. Chem.* 243: 3229-3231, 1968.
3. Rando, R.R. and Bloch, K.: The mechanism of action of β -hydroxydecanoyl thioester dehydrase. *J. Biol. Chem.* 243: 5627-5634, 1968.
4. Rando, R.R.: Conformational and solvent effects on carbene reactions. *J. Amer. Chem. Soc.* 92: 6706-6707, 1970.
5. Rando, R.R.: The effector-site labeling of the lac repressor. *Nature New Biol.* 234: 183-184, 1971.
6. Rando, R.R.: Conformational and medium effects on carbene reactions. *J. Amer. Chem. Soc.* 94: 1629-1631, 1972.
7. Sohn, M.B., Jones, M., Jr., Hendrick, M.E., Rando, R.R., and Doering, W. von E.: On synthesis of alkyl diazopropionates. *Tetrahedron Lett.* 1: 53-56, 1972.
8. Rando, R.R.: *In situ* generation of irreversible enzyme inhibitors. *Nature New Biol.* 237: 53, 1972.
9. Rando, R.R.: 3-Bromoallyl amine induced irreversible inhibition of monoamine oxidase. *J. Amer. Chem. Soc.* 95: 4438-4439, 1973.
10. Rando, R.R. and de Mairena, J.: Propargyl amine induced irreversible inhibition of non-flavin linked amine oxidases. *Biochem. Pharmacol.* 23: 463-467, 1974.
11. Rando, R.R.: The chemistry and enzymology of "kcat" inhibitors. *Science* 185: 320-324, 1974.
12. Rando, R.R.: β,γ -Unsaturated amino acids as irreversible enzyme inhibitors. *Nature* 250: 586-587, 1974.
13. Rando, R.R.: Allyl alcohol induced irreversible inhibition of yeast alcohol dehydrogenase. *Biochem. Pharmacol.* 23: 2328-2331, 1974.
14. Rando, R.R.: Mechanism-based irreversible enzyme inhibition. *Ann. Rev. Med. Chem.* 9: 234-243, 1974.
15. Rando, R.R.: Irreversible inhibition of aspartate aminotransferase by 2-amino 3-butenic acid. *Biochemistry* 13: 3859-3863, 1974.
16. Relyea, N. and Rando, R.R.: Potent inhibition of ornithine decarboxylase by β,γ -unsaturated substrate analogs. *Biochem. Biophys. Res. Commun.* 64: 1184-1188, 1975.
17. Rando, R.R.: On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors. *Biochem. Pharmacol.* 24: 1153-1160, 1975.

18. Rando, R.R.: The mechanism of action of naturally occurring irreversible enzyme inhibitors. *Acct. Chem. Res.* **8**: 281-288, 1975.
19. Rando, R.R., Relyea, N. and Cheng, L.: The mechanism of the irreversible inhibition of aspartate aminotransferase by the bacterial toxin L-2-amino-4-methoxy-trans-3-butenoic acid. *J. Biol. Chem.* **251**: 3306-3312, 1976.
20. Rando, R.R. and Bangerter, F.W.: The irreversible inhibition of mouse brain γ -aminobutyric acid (GABA) - α -ketoglutaric acid transaminase by gabaculine. *J. Amer. Chem. Soc.* **98**: 6762-6764, 1976.
21. Rando, R.R.: Mechanism-based irreversible enzyme inhibitors. *Methods in Enzymol.* **65**: 28-41, 1977.
22. Rando, R.R.: Acetylenic irreversible enzyme inhibitors. *Methods in Enzymol.* **65**: 158-164, 1977.
23. Rando, R.R.: The fluorescent labeling of mitochondrial monoamine oxidase. *Mol. Pharmacol.* **17**: 726-734, 1977.
24. Rando, R.R. and Bangerter, F.W.: The reaction of gabaculine with pyridoxal phosphate. *J. Amer. Chem. Soc.* **99**: 5141-5145, 1977.
25. Rando, R.R. and Eigner A.: The pseudoirreversible inhibition of mitochondrial monoamine oxidase by allyl amine. *Mol. Pharmacol.* **13**: 1005-1013, 1977.
26. Rando, R.R.: The mechanism of the irreversible inhibition of γ -aminobutyric acid (GABA)- β -ketoglutaric acid transaminase by the neurotoxin gabaculine. *Biochemistry* **16**: 4604-4610, 1977.
27. Rando, R.R. and Bangerter, F.W.: The *in vivo* irreversible inhibition of GABA transaminase by gabaculine. *Biochem. Biophys. Res. Commun.* **76**: 1276-1281, 1977.
28. Gehring, H., Rando, R.R. and Christen, P.: Active-site labeling of aspartate aminotransferases by the β , γ -unsaturated amino acid vinyl glycine. *Biochemistry* **16**: 4832-4836, 1977.
29. Esake, M., Suzuki, T., Tanaka, H., Soda, K., and Rando, R.R.: Deamination and addition reactions of vinyl glycine by L-methionine- γ -lyase. *FEBS Lett.* **84**: 309-312, 1977.
30. Orr, G. and Rando, R.R.: Synthetic ConA receptors and erythrocyte agglutination. *Nature* **272**: 722-725, 1978.
31. Rando, R.R.: The design of highly specific enzyme inactivators. In: *Theory and Practice in Affinity Techniques* (Eckstein, F. and Sundaram, P.V., Eds.), Academic Press, NY, pp. 135-150, 1978.
32. Rando, R.R.: Specific inhibitors of GABA metabolism. In: *GABA-Neurotransmitters* (Kofod, H., Kroghsgaard, J., and Kjaer, S., Eds.), Academic Press, NY, pp. 228-235, 1978.

33. Rando, R.R.: Principles of catalytic enzyme inhibition. In: *Enzyme Activated Irreversible Inhibitors* (Seiler, N., Jung, M.J. and Koch-Weser, J., Eds.), Proceedings of the International Symposium on Substrate-induced Irreversible Inhibitors of Enzymes, Elsevier/North Holland Press, NY, pp. 13-27, 1978.
34. Chrystal, E., Bey, P. and Rando, R.R.: The irreversible inhibition of L-glutamate decarboxylase by (2RS, 3E)-2-methyl-3,4 didehydroglutamic acid. *J. Neurochem.* **32**: 1501-1507, 1979.
35. Rando, R.R., Orr, G.A., and Bangerter, F.W.: Synthetic glycolipids and the lectin mediated aggregation of liposomes. *J. Biol. Chem.* **254**: 4721-4725, 1979.
36. Rando, R.R., Orr, G.A., and Bangerter, F.W.: Threshold effects on the ConA mediated agglutination of modified erythrocytes. *J. Biol. Chem.* **254**: 8318-8323, 1979.
37. Rando, R.R. and Bangerter, F.W.: Threshold effects and the lectin-mediated agglutination of liposomes. *J. Supramolec. Struct.* **11**: 295-309, 1979.
38. Rando, R.R.: On the labeling of oxidized cell surface membranes by acyl hydrazides. *Biochim. Biophys. Acta* **557**: 354-362, 1979.
39. Rando, R.R.: Natural and Synthetic k_{cat} inhibitors of transaminases and decarboxylases. In: *Drug Action and Design: Mechanism-based Enzyme Inhibitors* (Kalman, T.I., Ed.), Elsevier/North Holland, pp. 47-61, 1979.
40. Rando, R.R.: New modes of enzyme inactivator design. *Trends in Pharmacological Sciences* **1**: 168-171, 1980.
41. Rando, R.R., Slama, J. and Bangerter, F.W.: The functional incorporation of synthetic glycolipids into cells. *Proc. Natl. Acad. Sci. (USA)* **77**: 2510-2513, 1980.
42. Slama, J., and Rando, R.R.: The synthesis of glycolipids containing a hydrophilic spacer group. *Carbohydrate Res.* **88**: 213-221, 1981.
43. Slama, J., and Rando, R.R.: The lectin mediated aggregation of liposomes containing glycolipids with variable hydrophilic spacer arms. *Biochemistry* **19**: 4595-4600, 1981.
44. Yasuda, M., Toyama, S., Rando, R.R., Esaki, N., Tanizawa, K. and Soda, K.: Irreversible inactivation of L-ornithine: α -ketoglutarate δ -aminotransferase by gabaculine. *Agric. Biol. Chem. (Japan)* **44**: 3005-3006, 1980.
45. Kuo, D. and Rando, R.R.: The irreversible inhibition of glutamate decarboxylase by α -fluoromethylglutamic acid. *Biochemistry* **20**: 506-511, 1981.
46. Rando, R.R., Bangerter, F.W. and Farb, D.H.: The inactivation of γ -amino-butyric acid transaminase in embryonic spinal cord neuronal cell cultures. *J. Neurochem.* **36**: 985-990, 1981.

Rando, R.R.: The hemi-³H labeling of glutamate decarboxylase in vivo. *J. Biol. Chem.* **256**:

48. Rando, R.R.: Specific enzyme inactivators *in vitro* and *in vivo*. In: *32nd Mosbach Colloquium Structural and Functional Aspects of Enzyme Catalysis* (Eggerer, H., Ed.), Springer-Verlag, Berlin, pp. 131-135, 1981.
49. Parkinson, D., Baughman, R., Masland, R.H. and Rando, R.R.: Dopamine metabolism following irreversible inactivation of aromatic amino acid decarboxylase in retina. *J. Neurosci.* **1**: 1205-1210, 1981.
50. Parkinson, D. and Rando, R.R.: Evidence for a neurotransmitter role for 5-hydroxytryptamine in chick retina. *J. Neurosci.* **1**: 1211-1217, 1981.
51. Rando, R.R., Bangerter, F.W. and Alecio, M.R.: The synthesis and properties of a functional fluorescent cholesterol analog. *Biochim. Biophys. Acta* **684**: 12-20, 1982.
52. Alecio, M.R. and Rando, R.R.: Threshold effects on the lectin-mediated aggregation of liposomes: Influence of the diameter of the liposomes. *J. Membr. Biol.* **67**: 137-141, 1982.
53. Rando, R.R. and Bangerter, F.W.: The rapid intermembraneous transfer of retinoids. *Biochem. Biophys. Res. Commun.* **104**: 430-436, 1982.
54. Alecio, M.R., Golan, D.E., Veatch, W.R. and Rando, R.R.: The use of a fluorescent cholesterol derivative to measure the lateral mobility of cholesterol in membranes. *Proc. Natl. Acad. Sci. (USA)* **79**: 5171-5174, 1982.
55. Rando, R.R., Coburn, J. and Parkinson, D.: The differential effects of GABA-transaminase inactivation in the chick retina and brain. *J. Neurochem.* **39**: 1147-1151, 1982.
56. Wong, C.G. and Rando, R.R.: The inactivation of bovine opsin by all-trans-retinoyl fluoride. *J. Amer. Chem. Soc.* **104**: 7374-7375, 1982.
57. Parkinson, D. and Rando, R.R.: The effects of light on dopamine metabolism in the chick retina. *J. Neurochem.* **40**: 39-46, 1983.
58. Parkinson, D. and Rando, R.R.: Effect of light on dopamine turnover and metabolism in rabbit retina. *Invest. Ophthalm.* **24**: 384-388, 1983.
59. Rando, R.R. and Chang, A.: Studies on the catalyzed interconversions of vitamin A derivatives. *J. Amer. Chem. Soc.* **105**: 2879-2882, 1983.
60. Golan, D.E., Alecio, M.R., Veatch, W.R. and Rando, R.R.: Lateral mobility of phospholipid and cholesterol in the human erythrocyte membrane: Effects of protein on lipid interactions. *Biochemistry* **23**: 332-339, 1984.
61. Lukton, D. and Rando, R.R.: On the amine catalyzed isomerization of vitamin A aldehydes. *J. Amer. Chem. Soc.* **106**: 258-259, 1984.
62. Wong, C.G. and Rando, R.R.: The specific reaction of 9-cis-retinoyl fluoride with bovine opsin. *Biochemistry* **23**: 20-27, 1984.
- Rando, R.R.: Mechanisms of action of retinoids in the visual system.
64. Parkinson, D. and Rando, R.R.: Ontogenesis of dopaminergic neurons in the postnatal rabbit retina: Pre- and post-synaptic elements. *Devel. Brain Res.* **13**: 207-218, 1984.

65. Lukton, D. and Rando, R.R.: Catalysis of vitamin A aldehyde isomerization by primary and secondary amines. *J. Amer. Chem. Soc.* 106: 4525-4531, 1984.
66. Young, N. and Rando, R.R.: The stereospecific activation of protein kinase C. *Biochem. Biophys. Res. Commun.* 122: 818-823, 1984.
67. Bernstein, P.S., Lichtman, J.R. and Rando, R.R.: Non-stereospecific biosynthesis of 11-cis-retinal in the eye. *Biochemistry* 24: 487-492, 1985.
68. Bernstein, P.S. and Rando, R.R.: The specific inhibition of 11-cis-retinyl palmitate formation in the frog eye by diaminophenoxypentane, an inhibitor of rhodopsin regeneration. *Vision Res.* 25: 741-748, 1985.
69. Calhoon, R.D. and Rando, R.R.: The biochemical properties of 9-cis and all-trans retinoylopsins. *Biochemistry* 24: 3029-3034, 1985.
70. Boni, L.T. and Rando, R.R.: The nature of protein kinase C activation by physically defined phospholipid vesicles and diacylglycerols. *J. Biol. Chem.* 260: 10819-10825, 1985.
71. Calhoon, R.D. and Rando, R.R.: All-trans-retinoids and dihydroretinoids as probes of the role of chromophore structure in rhodopsin activation. *Biochemistry* 24: 6446-6452, 1985.
72. Longstaff, C., and Rando, R.R.: Methylation of the active-site lysine of rhodopsin. *Biochemistry* 24: 8137-8145, 1985.
73. Bernstein, P.S., Lichtman, J.R., and Rando, R.R.: Short-circuiting the visual cycle with retinotoxic aromatic amines. *Proc. Natl. Acad. Sci. (USA)* 83: 1632-1635, 1986.
74. Bernstein, P.S. and Rando, R.R.: In vitro isomerization of all-trans- to 11-cis-retinoids occurs at the alcohol oxidation state. *Invest. Ophthalm. Vis. Sci. (suppl.)* 27: 295, 1986.
75. Bernstein, P.S., Fulton, B.S., and Rando, R.R.: Mechanism of action of aromatic amines that short-circuit the visual cycle. *Biochemistry* 25: 3370-3377, 1986.
76. Longstaff, C., Calhoon, R.D., and Rando, R.R.: Deprotonation of the Schiff base of rhodopsin is obligate in the activation of the G-protein. *Proc. Natl. Acad. Sci. (USA)* 83: 4209-4213, 1986.
77. Longstaff, C., Calhoon, R.D., and Rando, R.R.: Chemical modification of rhodopsin and its effect on regeneration and G-protein activation. *Biochemistry* 25: 6311-6319, 1986.
78. Bernstein, P.S. and Rando, R.R.: In Vivo isomerization of all-trans- to 11-cis-retinoids in the eye occurs at the alcohol oxidation state. *Biochemistry* 25: 6473-6478, 1986.
79. Fulton, B.S. and Rando, R.R.: Mechanism of isomerization of 11-cis-retinal in lipid dispersions by aromatic amines. *Biochemistry* 26: 110-114, 1987.
80. Bernstein, P.S., Law, W.C., and Rando, R.R.: Isomerization of all-trans-retinoids to 11-cis-retinoids in vitro. *Proc. Natl. Acad. Sci. (USA)* 84: 1849-1853, 1987.

Bernstein, P.S. and Rando, R.R.: Biochemical characterization of the retinoid isomerase system of the eye. *Invest. Ophthalm. Vis. Sci. (suppl.)* 28: 250, 1987.

82. Law, W.C. and Rando, R.R.: Mechanistic studies on the *in vitro* biosynthesis of 11-cis-retinoids from all-trans-retinol. *Invest. Ophthalm. Vis. Sci. (suppl.)* **28**: 250, 1987.
 83. Fulton, B. and Rando, R.R.: Retinyl ester formation and the biosynthesis of 11-cis-retinoids by bovine pigment epithelium membranes. *Biochemistry*, **26**, 7938-7945, 1987.
 84. Rando, R.R.: The bioorganic chemistry of vision. In: *Chemistry and Biology of Synthetic Retinoids* (Dawson, M.I. and Okamura, W.H., Eds.), CRC Press, 1-27, 1990.
 85. Longstaff, C., Seckler, B., Calhoon, R.D., and Rando, R.R.: Active-site methylation and the mechanisms of action of rhodopsin and bacteriorhodopsin. In: *Biophysical Studies of Retinal Proteins* (Ebrey, T., Frauenfelder, H., Honig, B., and Nakanishi, K., Eds.), pp. 64-70 Univ. of Illinois Press, 1987.
 86. Longstaff, C. and Rando, R.R.: Deprotonation of the Schiff base of bacteriorhodopsin is obligate in light-induced proton pumping. *Biochemistry* **26**: 6107-6113, 1987.
 87. Bernstein, P.S., Law, W.C., and Rando, R.R.: Biochemical characterization of the retinoid isomerase system of the eye. *J. Biol. Chem.* **262**: 16848-16857, 1987.
 88. Rando, R.R.: The Regulation of Protein Kinase C Activity by Lipids. *FASEB Journal* **2**: 2348-2355, 1988.
 89. Law, W.C. and Rando, R.R.: Stereochemical inversion at C-15 accompanies the enzymatic isomerization of all-trans- to 11-cis-retinoids. *Biochemistry* **27**: 4147-4152, 1988.
 90. Law, W.C., Canonica, S., Derguini, F., Nakanishi, K., and Rando, R. R.: The necessity of an intact polyene for the biological isomerization of vitamin A. *J. Amer. Chem. Soc.* **110**: 5915-5917, 1988.
 91. Govindjee, R., Dancshazy, Zs., Ebrey, T.G., Longstaff, C. and Rando, R.R.: Photochemistry of methylated and permethylated bacteriorhodopsin and rhodopsin. *Biophysical Journal* **53**: 379a, 1988.
 92. Govindjee, R., Dancshazy, Zs., Ebrey, T.G., Longstaff, C. and Rando, R.R.: Photochemistry of methylated rhodopsin. *Photochem. Photobiol.* **48**: 493-496, 1988.
 93. Govindjee, R., Dancshazy, Zs., Ebrey, T.G., Longstaff, C. and Rando, R.R.: Photochemistry of monomethylated and permethylated bacteriorhodopsin. *Biophysical Journal* **54**: 557-562, 1988.
 94. Barry, R.J. and Rando, R.R.: Solubilization and partial purification of the retinoid isomerase an ester synthetase of the mammalian eye. *Invest. Ophthalm. Vis. Sci. (suppl.)* **29**: 386, 1988.
 95. Law, W.C. and Rando, R.R.: Stereochemical and mechanistic studies on the retinoid isomerase. *Invest. Ophthalm. Vis. Sci. (suppl.)* **29**: 122, 1988.
 96. Molleyres, L.P., and Rando, R.R.: Structural studies on the diglyceride mediated activation of protein kinase C. *J. Biol. Chem.*, **263**: 14832-14838, 1988.
- Perez-Sala, D., Avuso, M., Riccio, V., Parrilla, R., and Rando, R.R.: The interaction of cycloserine with pyruvate and other biologically relevant α -ketoacids. *Biochem. Pharm.* **38**: 1037-1044, 1989.

98. Law, W. C., Kim, S., and Rando, R. R.: The stereochemistry of the visual cycle. *J. Amer. Chem. Soc.* 111: 793-795, 1989.
99. Ganter, U., Schmid, E. D., Perez-Sala, D., Rando, R. R., and Siebert, F.: Removal of the 9-methyl group of retinal inhibits signal transduction in the visual process. *Biochemistry* 28: 5954-5962, 1989.
100. Pajares, M. A., and Rando, R. R.: The active - site environment of rhodopsin. *J. Biol. Chem* 264: 6804-6809, 1989.
101. Barry, R. J., Cañada, F. J., and Rando, R. R.: Solubilization and partial purification of retinyl ester synthetase and retinoid isomerase from bovine ocular pigment epithelium. *J. Biol. Chem.* 264: 9231-9238, 1989
102. Rando, R. R., Cañada, J., Deigner, P. S., and Law, W. C.: Is there a retinol isomerase? *Invest. Opth. Vis. Sci. (suppl.)* 30: 331, 1989
103. Ganter, U. M., Krautle, R., Rando, R. R., and Siebert, F. : The comparison of the photoreactions of rhodopsin and bacteriorhodopsin.: An FTIR investigation using modified pigments. in *Molecular Physiology of Retinal Proteins*, T. Hara, Ed., pp. 55-60, Yamada Science Foundation, Japan, 1988.
104. Deigner, P. S., Law, W. C., Cañada, F. J. and Rando, R. R.: Membranes as the energy source in the endergonic transformation of vitamin A to 11-*cis*-retinol. *Science* 244: 968-971, 1989.
105. Law, W. C. and Rando, R. R.:The molecular basis of retinoic acid induced night blindness. *Biochem. Biophys. Res. Comm.* 161: 825-829, 1989.
106. Bernstein, P. S. and Rando, R. R.:Assay of the retinoid isomerase system of the eye. *Methods in Enzymology* 189: 411-417, 1990.
107. Rando, R. R. and Bangerter, F. W.:Intermembranous transfer of retinoids. *Methods in Enzymology* 189: 494-502, 1990.
108. Nakamura, H., Kishi, Y., Pajares, M. A. and Rando, R. R.:The structural basis of protein kinase C activation by tumor promoters. *Proc. Nat. Acad. Sci. (USA)* 86: 9672-9676, 1989.
109. Seckler, B. and Rando, R. R.:Schiff-base deprotonation is mandatory for light-dependent rhodopsin phosphorylation. *Biochemical Journal* 264: 489-493, 1989.
110. Trehan, A., Cañada, F. J. and Rando, R. R.:Inhibitors of retinyl ester formation also prevent the biosynthesis of 11-*cis*-retinol. *Biochemistry* 29, 309-312, 1990.
111. Krautle, R., Gartner, W., Ganter, U. M., Longstaff, C., Rando, R. R., and Siebert, F.:The photoreaction of active-site methylated bacteriorhodopsin: An investigation using static and time-resolved infrared difference spectroscopy. *Biochemistry* 29: 3915-3923, 1990.

Rando, R. R.: The chemistry of vitamin A and vision. *Angewandte Chemie (Int. Ed. Engl.)* 29: 461-480, 1990. Also published in German as Die Chemie des Vitamins A und des Sehvorgangs. *Angewandte Chemie*. 102: 507-526, 1990.

113. Lai, R. K., Pérez-Sala, D., Canada, F. J., and Rando, R. R.: The γ subunit of transducin is farnesylated. *Proc. Nat. Acad. Sci (USA)* **87**: 7673-7677, 1990.
114. Kong, F., Kishi, Y., Pérez-Sala, D., and Rando, R. R.: The stereochemical requirement for protein kinase c activation by 3-methyldiglycerides matches that found in naturally occurring tumor promoter aplysiatoxins. *FEBS Lett.* **274**: 203-206, 1990.
115. Cañada, F. J., Law, W. C., Rando, R. R., Yamamoto, T., Derguini, F., and Nakanishi, K.: Substrate specificities and mechanism in the enzymatic processing of vitamin A into 11 *cis*-retinol. *Biochemistry* **29**: 9690-9697, 1990.
116. Ganter, U. M., Longstaff, C., Pajares, M. A., Rando, R. R., and Siebert, F.: Fourier transform infrared studies of active-site-methylated rhodopsin: Implications for chromophore-protein interaction, transducin activation, and the reaction pathway. *Biophysical Journal* **59**: 640-644, 1991.
117. Rando, R. R., Bernstein, P. S. and Barry, R. J.: New insights into the visual cycle. *Progress in Retinal Research* **10**: 161-178, 1991.
118. Rando, R. R.: Membrane phospholipids as an energy source in the operation of the visual cycle. *Biochemistry* **30**: 595-602, 1991.
119. Kong, F., Kishi, Y., Pérez-Sala, D., and Rando, R. R.: Identifying the debromoaplysiatoxin pharmacophore which is responsible for protein kinase c activation. *Proc. Nat. Acad. Sci. (USA)* **88**: 1973-1976, 1991.
120. Rando, R. R.: Membrane phospholipids and the dark side of vision. *J. Bioenergetics Biomembranes* **23**: 133-146, 1991.
121. Pérez-Sala, D., Tan, E. W., Cañada, F. J., and Rando, R. R.: Methylation and demethylation reactions of rod outer segment G proteins. *Proc. Nat. Acad. Sci. (USA)* **88**: 3043-3046, 1991.
122. Tan, E. W., Pérez-Sala, D., Cañada, F. J., and Rando, R. R.: Identifying the recognition unit for G protein methylation. *J. Biol. Chem.* **266**: 10719-10722, 1991.
123. Albers, M. W., Liu, J., Wilkinson, S. E., Wadsworth, J., Pérez-Sala, D., Rando, R. R., Nixon, J. S., Schrieber, S. L.: FKBP, thought to be identical to PKC ζ -2, does not inhibit protein kinase C. *BioMed. Chem. Lett.* **1**: 205-210, 1991.
124. Tan, E. W., Pérez-Sala, D., and Rando, R. R.: Heteroatom requirements for substrate recognition by GTP-binding protein methyltransferase. *J. Am. Chem. Soc.* **113**: 6299-6300, 1991.
125. Gilbert, B., Tan, E. W., Pérez-Sala, D., and Rando, R. R.: Structure-activity studies on the isoprenylated protein methyltransferase. *J. Am. Chem. Soc.* **114**: 3966-3973, 1992.
126. Rando, R. R. and Kishi, Y.: Structural basis of protein kinase C activation by diacylglycerols and tumor promoters. *Biochemistry* **31**: 2211-2218, 1992.
127. Shi, Y. Q. and Rando, R. R.: The kinetic mechanism of isoprenylated protein methyltransferase. *Proc. Nat. Acad. Sci. (USA)* **89**: 1111-1115, 1992.

128. Pérez-Sala, D., Gilbert, B. A., Tan, E. W. and Rando, R. R.: Prenylated protein methyltransferases do not distinguish between farnesylated and geranylgeranylated substrates. *Biochem. J.*, **284**: 835-840, 1992.
129. Rando, R. R. and Kishi, Y.: Structural basis of protein kinase C activation by diacylglycerols and tumor promoters in *Protein Kinase C: Current Concepts and Future Perspectives*, E. R. Eppand and D. Lester, Eds., pp. 41-61, Ellis Horwood, Chichester, England, 1992.
130. Tan, E. W. and Rando, R. R.: Identification of an isoprenylated cysteine methyl ester hydrolase activity in bovine rod outer segment membranes. *Biochemistry*, **31**: 5572-5578, 1992.
131. Ma, Y.-T. and Rando, R. R.: A microsomal protease that specifically cleaves isoprenylated peptides. *Proc. Nat. Acad. Sci.*, **89**: 6275-6279, 1992.
132. Ma, Y.-T., Chaudhuri, A., and Rando, R. R.: Substrate specificity of the isoprenylated protein endoprotease. *Biochemistry*, **31**: 11772-11777, 1992.
133. Rando, R. R.: Molecular mechanisms in visual pigment regeneration. *Photochem. & Photobiol.*, **56**: 1145-1156, 1992.
134. Rando, R. R.: Posttranslational modifications of retinal G proteins in *Structures and Functions of Retinal Proteins*, Ed. J. L. Rigaud, **221**, 365-368, J. Libbey Eurotext Ltd., London, 1992.
135. Shi, Y.-Q., Hubacek, I. and Rando, R. R.: Kinetic mechanism of lecithin retinol acyl transferase. *Biochemistry*, **32**: 1257-1263, 1993.
136. Rando, R. R., Shi, Y. Q., Furuyoshi, S., and Hubacek, I.: Mechanistic Studies on lecithin retinol acyl transferase *Invest. Ophthalm. Vis. Sci. (suppl.)* **34**: 1198, 1993.
137. Rando, R. R.: Retinoid isomerization reactions in the visual system in *Vitamin A in Health and Disease*, R. Blomhoff, Ed., Chap. 18 (pp. 503-529), Marcel Dekker, New York, 1994.
138. Shi, Y.-Q., Furuyoshi, S., Hubacek, I. and Rando, R. R.: Affinity Labeling of lecithin retinol acyl transferase. *Biochemistry*, **32**: 3077-3080, 1993.
139. Furuyoshi, S., Shi, Y.-Q. and Rando, R. R.: Acyl group transfer from the sn-1 position of phospholipids in the biosynthesis of n-dodecyl palmitate. *Biochemistry*, **32**: 5425-5430, 1993.
140. Ma, Y.-T., Gilbert, B. A. and Rando, R. R.: Inhibitors of the isoprenylated protein endoprotease. *Biochemistry*, **32**: 2386-2393, 1993.
141. Ma, Y.-T. and Rando, R. R.: Endoproteolysis of non-CAAX containing isoprenylated peptides. *FEBS LETT*, **332**: 105-110, 1993.
142. Ma, Y.-T. and Rando, R. R.: Isoprenylated protein endoprotease. *Methods in Enzymol.*, **244**: 632-639, 1994.

rbach, and Rando, R. R.: Isomerization of 11-*trans* retinoic acid to 13-*cis* retinoic acid. *Biochemical. J.*, **299**: 459-465, 1994

144. Ma, Y.-T., Gilbert, B. A. and Rando, R. R.: Farnesylcysteine analogs to probe the role of the isoprenylated protein methyltransferase. *Methods in Enzymol*, **250**: 226-234, 1995.
145. Gilbert, B. A., Ma, Y.-T. and Rando, R. R.: Inhibitors of prenylated protein endoprotease. *Methods in Enzymol*, **250**: 206-215, 1995.
146. Rando, R. R.: Isomerization reactions of retinoids in the visual system. *Pure and Applied Chemistry*, **66**: 989-994, 1994.
147. Ma, Y. T., Shi, Y.-Q., McGrail, S., Ware, J. A. and Rando, R. R.: Mechanistic studies on human platelet isoprenylated protein methyltransferase: Farnesylcysteine analogs block platelet aggregation without inhibiting the methyltransferase. *Biochemistry*, **33**: 5414-5420, 1994.
148. Ding, J., Lu, D. J., Pérez-Sala, D., Ma, Y. T., Maddox, J., F., Gilbert, B. A., Badwey, J. A. and Rando, R. R.: Farnesyl-L-Cysteine analogs can inhibit or initiate superoxide release by human neutrophils. *J. Biol. Chem.*, **269**: 16837-16844, 1994.
149. Rando, R. R. The Retinoids, in Molecular Biology: and Biochemistry, 820-824, VCH Publishers, New York, 1995.
150. Bernstein, P. S., Choi, S. Y., Ho, Y. C. and Rando, R. R.: The detection of novel retinoic acid binding proteins in the bovine retina using photoaffinity labeling. *Invest. Ophthalm. Vis. Sci. (suppl.)* **35**: 2060, 1994.
151. Parish, C. A. and Rando, R. R.: Functional significance of G protein carboxymethylation. *Biochemistry* **33**: 9986-9991, 1994.
152. Urbach, J. and Rando, R. R.: Thiol dependent isomerization of all-trans-retinoic acid to 9-cis-retinoic acid. *FEBS Lett.* **351**: 429-432, 1994.
153. Giner, J.-L. and Rando, R. R.: A novel methyltransferase modifying the carboxy terminal bis (geranylgeranyl)-CAC structure of of small GTP-binding proteins. *Biochemistry* **33**: 15116- 15123, 1994.
154. Bernstein, P. B., Choi, S.-Y., Ho, Y.-C., and Rando, R. R. : Photoaffinity labeling of retinoic acid-binding proteins. *Proc. Nat. Acad. Sci.*, **92**: 654-658, 1995.
155. Gilbert, B. A., Lim, Y.-H., Ding, J., Badwey, J. A., and Rando, R. R. : Farnesyl thiotriazole, A potent neutrophil agonist and structurally novel activator of protein kinase C. *Biochemistry* **34**: 3916-3920, 1995.
156. Parish, C. A., Smrcka, A. V., and Rando, R. R. : Functional Significance of $\beta\gamma$ -subunit carboxymethylation for the activation of phospholipase C and phosphoinositide 3 kinase. *Biochemistry* **34**: 7722-7727, 1995.
157. Wang, Y. and Rando, R. R. : Specific binding of aminoglycoside antibiotics to RNA. *Chemistry & Biology* **2**: 281-290, 1995.

Gilbert, B. A. and Rando, R. R.: Molecular Biology of the Retinoids: Synthesis and utilization of a biotinylated pepstatin photoprobe. *Mol. Cell. Biochem.* **150**: 8061-8066, 1995.

159. Rando, R. R. :Chemical biology of the retinoids. in *The Encyclopedia of Molecular Biology and Molecular Medicine*, Vol. 5, 322-327, VCH Publishers, New York., 1996
160. Rando, R. R. :Chemical biology of isoprenylation/methylation. *Biochim. Biophys. Acta.* 1300: 5-16, 1996.
161. Cheng, H., Parish, C. A., and Rando, R. R. : A Novel endoprotease responsible for the specific cleavage of the transducin γ subunit. *Biochemistry* 34: 16662--16671, 1996.
162. Chen, Y. L., Ma, Y. T., and Rando, R. R. : Solubilization, partial purification, and affinity labeling of the membrane bound isoprenylated protein endoprotease. *Biochemistry* 35: 3227-3273, 1996.
163. Rando, R. R. :Polyenes and vision. *Chemistry & Biology* 3: 255-262, 1996.
164. Rando, R. R. : Chemistry and biology of isoprenylation/methylation. *Biochemical Society Transactions* 24: 682-687, 1996..
165. Parish, C. A., Smrcka, A. V., and Rando, R. R. : The role of G protein methylation in the function of a geranylgeranylated isoform. *Biochemistry* 35: 7499-7505, 1996.
166. Parish, C. A. and Rando, R. R. : Isoprenylation/methylation of proteins enhances membrane association by a hydrophobic mechanism. *Biochemistry* 35: 8473-8477, 1996.
167. Rando, R. R.: The isoprenylated protein endoprotease. *Handbook of Proteolytic Enzymes*, (in press) Academic Press.
168. Xu, Y., Gilbert, B. A., Rando, R. R., Chen, L., and Tashjian, A. H. : Inhibition of capacitive Ca^{2+} entry into cells by farnesylcysteine analog. *Molecular Pharmacology* 50: 1495-1501, 1996.
169. Wang, Y., Killian, J., Hamasaki, K., and Rando, R. R. : RNA molecules that specifically and stoichiometrically bind aminoglycoside antibiotics with high affinities. *Biochemistry* 35: 12338-12346, 1996.
170. Wang, Y., Hamasaki, K., and Rando, R. R. : Specificity of aminoglycoside binding to RNA constructs derived from the 16S decoding region and the HIV-RRE activator region. *Biochemistry* 36: 768-779, 1996.
171. Parish, C. A. and Rando, R. R. : On the mechanism of the inhibition of transducin function by farnesylcysteine analogs. *Biochemistry* 36: 2686-2693, 1997.
172. Marom, M., Parish, C. A., Giner, J.-L., and Rando, R. R. : Minimal structural requirements for diglyceride-site directed activators of protein kinase C. *Tetrahedron* 53, 10041-10050, 1997.
173. Gilbert, B. A., Ma, S., Wathan, S. T. and Rando, R. R. :RNA Aptamers that specifically bind to a K ras-derived farnesylated peptide. Symposium in Print on "Strategies for RNA Recognition" in *Bioorganic and Medicinal Chemistry* 5: 1115-1122, 1997.

Hamasaki, K. and Rando, R. R. : Specific binding of aminoglycosides to a human tRNA^{val} construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. *Biochemistry* 36: 12323-12328, 1997.

175. Bernstein, P. S., Balashov, M. A., Tsong, E. D. and Rando, R. R.: Retinal tubulin binds macular carotenoids. *Invest. Ophthalmol. Vis. Sci.* **38**: 167-175, 1997
176. Hamasaki, K., Killian, J., Cho, J. and Rando, R. R.: Minimal RNA constructs that specifically bind aminoglycoside antibiotics with high affinities. *Biochemistry* **37**: 656-663, 1998.
177. Kishi, Y. and Rando, R.R.: The structural basis of protein kinase C activation by tumor promoters. *Accounts of Chemical Research* **31**, 163-172 1998.
178. Winston, A. and Rando, R.R.: Regulation of isomerohydrolase activity in the visual cycle. *Biochemistry* **37**, 2044-2050 1998.
179. Cho, J., Hamasaki, K. and Rando, R. R.: The binding site of a specific aminoglycoside binding RNA molecule. *Biochemistry* **37**, 4985-4992 1998.
180. Hamasaki, K. and Rando, R. R.: A high-throughput fluorescence screen to monitor the specific binding of antagonists to RNA targets. *Anal. Biochem.* **261**, 183-190 1998.
181. Tok, J. B.-H. and Rando, R. R.: Simple aminols as aminoglycoside surrogates. *J. Am. Chem. Soc.* **120**, 8279-8280 1998.
182. Lee, S., Floss, H.G., Gilbert, B.A. Rando R.R.: Steric course of the methyl transfer from adomet to s-farnesyl-3-thiopropionate by G-protein methyltransferase. *J. Org. Chem.* **63**:898-899, 1998.
183. Perez-Sala, D., Gilbert, B.A., Rando, R.R., Cañada, F.J.: Analogs of farnesylcysteine induce apoptosis in HL-60 cells. *FEBS Letters.* **426**:319-324, 1998.
184. Choo, D.W., Cheung, E., Rando, R.R.: Lack of effect of RPE65 removal on the enzymatic processing of all-*trans*-retinol into 11-*cis*-retinol in vitro. *FEBS Letters.* **440**:195-198, 1998.
185. Tok, J.B.-H., Cho, J.H., Rando, R.R.: Aminoglycoside antibiotics are able to specifically bind the 5'-untranslated region of thymidylate synthase messenger RNA. *Biochemistry.* **38**:199-206, 1999.
186. Ruiz, A., Winston, A., Lim, Y.H., Gilbert, B.A., Rando, R.R., Bok, D.: Molecular and biochemical characterization of lecithin retinol acyltransferase. *J. Biol. Chem.* **274**:3834-3841, 1999.
187. Tok, J.B.-H., Cho, J.H., and Rando, R.R.: Aminoglycoside hybrids as potent RNA antagonists. *Tetrahedron.* **55**:5741-5758, 1999.
188. Cho, J. and Rando, R. R.: Specificity in the binding of aminoglycosides to HIV-RRE RNA. *Biochemistry* **38**:8548-8554, 1999.
189. Mondal, M.S., Wang, Z., Seeds, A.M., Rando, R.R.: The specific binding of small molecule isoprenoids to rhoGDP dissociation inhibitor (rhoGDI). *Biochemistry* **39**: 406-412, 2000.
190. Mondal, M.S. and Rando, R.R.: Isoprenylation, methylation, and transduction function. *Genet. Enzym.* **216**:451-464, 2000.

191. Winston, A. and Rando, R.R.: Quantitative measurements of isomerohydrolase activity. *Meth. Enzym.* 316:324-330, 2000.
192. Cho, J. and Rando, R. R.: Specific Binding of Hoechst 33258 to Site 1 Thymidylate Synthetase mRNA. *Nucleic Acids Research* 28:2158-2163, 2000.
193. Mondal, M.S., Ruiz, A., Bok, D., and Rando, R. R.: Lecithin retinol transferase contains cysteine residues essential for catalysis. *Biochemistry* 39: 5215-5220, 2000.
194. Tok, J.B.-H., Cho, J., Rando, R.R.: RNA aptamers that specifically bind to a 16S ribosomal RNA decoding region construct. *Nucleic Acids Research* 28: 2902-2910, 2000.
195. Guo, X., Ruiz, A., Rando, R.R., Bok, D., Gudas, L.J.: Esterification of all-*trans*-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of lecithin retinol acyltransferase in carcinoma lines. *Carcinogenesis* 21: 1925-1933, 2000.
196. Rando, R.R.: Specificity in the binding of aminoglycosides to RNA. *RNA Binding Antibiotics, Schroeder, R and Wallis, M. G. (Eds), Landes Biosciences*, Chapter 10, 2001.
197. Rando, R.R.: The Biochemistry of the Visual Cycle. *Chemical Reviews* 101: 1881-1896, 2001.
198. Mondal, M.S., Ruiz, A., Hu, J., Bok, D., Rando, R.R.: Two histidine residues are essential for catalysis by lecithin retinol acyl transferase. *FEBS Lett.* 489: 14-18, 2001.
199. Guo, X., Nanus, D.M., Ruiz, A., Rando, R.R., Bok, D., Gudas, L.J.: Reduced levels of retinyl esters and vitamin A in human renal cancers. *Cancer Res.* 61: 2774-2781, 2001.
200. Ryu, D.H. and Rando, R.R.: Aminoglycoside binding to human and bacterial A-site rRNA decoding region constructs. *Bioorg. and Med. Chem.* (In Press).